Apollo Fertility

Sector: Healthcare, Fertility and IVF Clinics  |  HQ: Chennai, Tamil Nadu, India  |  Founded: 2014  |  Employees: 1,500+

Listed as: Privately held  | 

Company overview

Apollo Fertility is the fertility and IVF (in-vitro fertilisation) clinic chain operated by Apollo Health and Lifestyle Limited, a subsidiary of Apollo Hospitals Enterprise Limited (NSE: APOLLOHOSP, BSE: 508869). Launched in 2014, the business operates over 20 fertility centres across major Indian cities offering a full range of assisted reproductive technology (ART) services including IVF, intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), egg freezing, sperm freezing, surrogacy support (within the legal framework), and reproductive endocrinology consultation. The chain is among the largest organised IVF networks in India alongside Nova IVF Fertility (TPG Capital owned), Indira IVF (Bain Capital owned), Cloudnine Hospitals (fertility specialty), Bloom IVF, and ART Fertility Clinics. Apollo Fertility centres are located in Chennai, Bengaluru, Hyderabad, Delhi NCR, Mumbai, Kolkata, Pune, Ahmedabad, Vizag, Madurai, Coimbatore, and other major cities. The chain leverages the Apollo Hospitals brand for credibility, accesses the broader Apollo network for cross-referrals and complex case management, and operates under the integrated Apollo Health and Lifestyle Limited governance.

Financial performance and recent trajectory

Disclosed revenue (FY25): ₹350 crore (FY 2024-25 estimate).

Competitive position

Apollo Fertility operates in the Indian organised IVF market estimated at over ₹4,500 crore in annual revenue and growing at low-to-mid teens CAGR. Principal competitors include Indira IVF (the largest by clinic count with over 110 centres, acquired by Bain Capital in 2023), Nova IVF Fertility (over 80 centres, owned by TPG Capital after the 2020 acquisition from Novamed Fertility), Cloudnine Hospitals (fertility specialty alongside maternity), Bloom IVF, ART Fertility Clinics (Indo-Middle East operator), Manipal Hospitals fertility chain, Akanksha IVF, Mother and Child Hospitals fertility chain, Cocoon Hospitals, and a long tail of standalone IVF clinics. The competitive moats are the Apollo Hospitals brand association supporting consumer trust, the multi-city footprint with concentration in tier-1 metros, the access to the broader Apollo medical infrastructure for complex case management, and the structured clinical protocols and quality discipline. The principal vulnerabilities are the structural pricing pressure as private equity-owned chains have invested heavily in volume-driven pricing, competitive intensity from Indira IVF and Nova IVF Fertility, the regulatory compliance complexity under the Assisted Reproductive Technology (Regulation) Act 2021 notified by the Ministry of Health, and the cyclical exposure to discretionary spending which can affect treatment cycle volumes.

Key risks

Competitive intensity from Indira IVF and Nova IVF Fertility scale ART Act 2021 and Surrogacy Act 2021 compliance complexity Discretionary spending sensitivity affecting cycle volumes

Outlook

Apollo Fertility was launched in 2014 by Apollo Health and Lifestyle Limited as the fertility specialty chain within the broader Apollo Hospitals ecosystem. The strategic rationale was the rapid growth of the Indian organised fertility market driven by rising incidence of infertility (estimated at 10 to 15 percent of Indian couples of reproductive age), urban lifestyle factors, delayed family planning, and increasing acceptance of ART procedures. The Indian IVF market had been highly fragmented with mostly standalone clinics; the consolidation through organised chains accelerated through the 2010s with Indira IVF, Nova IVF Fertility, and Apollo Fertility leading the structured network builds. The business is organised around the fertility specialty clinic model. Each Apollo Fertility centre typically has 2 to 6 reproductive endocrinology specialists, embryologists, IVF lab technicians, ultrasonographers, counsellors, and supporting staff. The clinical infrastructure includes the IVF laboratory (with controlled environment incubators, micromanipulation equipment, cryopreservation tanks), procedure rooms for oocyte retrieval and embryo transfer, ultrasound and consultation rooms, and laboratory support for blood work. Centre footprint is typically 6,000 to 12,000 square feet. The service portfolio includes IVF (the largest revenue contributor, with typical cycle pricing of ₹1.5 lakh to ₹3.5 lakh depending on location, protocol, and add-on services), ICSI (a specialised IVF technique for severe male factor infertility), IUI (a lower-intensity treatment for select fertility profiles, priced at ₹15,000 to ₹40,000 per cycle), egg freezing (a growing service segment for women preserving fertility for delayed family planning), sperm freezing, donor egg and donor sperm programmes (within the legal framework), preimplantation genetic testing for monogenic disorders and aneuploidy screening (PGT-M, PGT-A), and reproductive endocrinology consultation. Distribution and patient acquisition combines direct walk-in from advertising and brand recall, referrals from gynaecologists and general practitioners, the Apollo Hospitals network referrals, digital lead generation through Google and Meta, and corporate fertility benefit programmes which are an emerging channel as Indian employers add fertility coverage to employee health benefits. Financial trajectory has been growth-driven. Apollo Fertility revenue is estimated at approximately ₹220 crore in FY22, ₹275 crore in FY23, ₹310 crore in FY24, and approximately ₹350 crore in FY25 at CAGR of approximately 14 to 16 percent. EBITDA margins at mature fertility centres are typically 22 to 32 percent; Apollo Fertility's blended margin is estimated in the mid-twenties range. The business consolidates within Apollo Health and Lifestyle Limited. Recent strategic priorities include centre network expansion to over 30 centres by FY28, integration of advanced IVF technologies (time-lapse embryo monitoring, AI-assisted embryo selection, PGT-A), expansion of the embryology fellowship and training programme, and corporate fertility benefit programme partnerships. Strategy through 2025 to 2030 is anchored on four themes. First, network expansion in tier-2 cities where organised IVF penetration is below tier-1 metros and where Apollo brand recall is strong. Second, premium tier service offering including PGT-A, advanced embryo monitoring, and personalised stimulation protocols that command pricing premium. Third, corporate fertility benefit channel development with insurers and employers. Fourth, the ART Act 2021 compliance and the related operational adjustments around registered clinic standards, surrogacy regulation, and donor gametes management. The regulatory environment is the Assisted Reproductive Technology (Regulation) Act 2021 notified by the Ministry of Health and Family Welfare, which along with the Surrogacy (Regulation) Act 2021 establishes the comprehensive framework for ART clinics. The Act mandates registration of ART clinics and banks, prescribes qualifications for ART specialists and embryologists, regulates donor gametes management, restricts surrogacy to altruistic surrogacy for Indian couples, and provides for the National and State Boards for oversight. The Clinical Establishments (Registration and Regulation) Act 2010 framework applies in adopting states. The Pre-Conception and Pre-Natal Diagnostic Techniques Act 1994 governs sex selection prohibition that is strictly enforced. The Indian Council of Medical Research guidelines provide additional clinical practice frameworks. The Companies Act 2013 and SEBI LODR govern Apollo Hospitals Enterprise Limited disclosure. Risks include the structural pricing pressure from Indira IVF and Nova IVF Fertility, the regulatory compliance complexity under the ART Act 2021 and the Surrogacy Act 2021, competitive intensity in tier-1 metros particularly Mumbai, Delhi NCR, and Bengaluru, the cyclical exposure to discretionary spending affecting cycle volumes, and the structural risk of insurance coverage exclusion (Indian health insurance typically does not cover fertility treatments which limits the addressable population to higher-income out-of-pocket payers). Management quality is anchored by Apollo Health and Lifestyle Limited leadership with specialty clinical leadership from the senior reproductive endocrinology team. Statutory audit is conducted under SEBI LODR and Companies Act 2013 for the consolidated Apollo Hospitals Enterprise Limited. ESG positioning is moderate. ART services provide a meaningful social impact for couples facing infertility. Counselling services for the emotional dimensions of fertility treatment are an important social ESG component. Compliance with the ART Act 2021 and the Surrogacy Act 2021 ethical framework is critical for sector integrity.

KAMRIT point of view

Building or competing with Apollo?

KAMRIT advises promoters, family offices, and global enterprises evaluating greenfield entry into the healthcare sector. Our Bankable DPR with Cost Model and ROI benchmarks your project economics against the listed-company cost structure of Apollo and peers. The Execution Partnership tier covers everything from incorporation through commissioning. A 20-minute scoping call with our partners is free.

View all 1 related project report → Book a scoping call

Related KAMRIT project reports

These reports use Apollo Fertility in benchmarking and competitive analysis sections.

Disclaimer: This profile is compiled by KAMRIT Financial Services LLP for educational and benchmarking purposes only. It is not investment advice, a recommendation to buy or sell securities, or a solicitation. Stock data is provided by Yahoo Finance and may be delayed by up to 20 minutes. Company financial commentary draws on publicly available filings, exchange disclosures, and KAMRIT industry research. Readers should consult a SEBI-registered investment adviser before making investment decisions. KAMRIT is a financial services and compliance firm, not a SEBI-registered investment adviser.